Kornimate/medical-research-clean huggingface dataset:
prp vs prp+ivc for severe npdr

Conditions: Severe Nonproliferative Diabetic Retinopathy; Diabetic Retinopathy; Diabete Mellitus

Summary: the randomized clinical trial aims to compare the therapeutic effects between panretinal photocoagulation(prp) and prp combined with intravitreal conbercept (ivc) injection in severe npdr with/without diabetic macular edema patients.

this was a prospective, randomized, two-armed study to assess the efficacy and safety of intravitreal conbercept injection plus prp versus prp in the treatment of npdr patients with/without diabetic macular edema for a period of 1 year. this was an investigator-initiated study performed by department of ophthalmology, ruijin hospital affiliated with shanghai jiaotong university school of medicine.

Eligibility criteria:
inclusion criteria: type ii diabetic patients, 18 years and older, were included if the participants had: 1. severe non-pdr in either eyes with/without diabetic macular edema; 2. etdrs letters-measured best-corrected visual acuity (bcva) ranging from 20/40 to 20/320 snellen equivalent; 3. no previous treatment (of any type) in either eye. exclusion criteria: 1. history of prior laser treatment or vitrectomy in the study eye; 2. history of thromboembolic event - including myocardial infarction or cerebral vascular accident; 3. major surgery within the prior 6 months or planned within the next 28 days; 4. history of glaucoma or ocular hypertension; 5. loss of vision as a result of other causes; 6. history of systemic corticosteroid therapy within the last 3 months; 7. severe systemic disease other than diabetes mellitus; 8. known coagulation abnormalities or current use of anticoagulative medication other than aspirin 9. any condition that could affect followup or documentation (including preretinal or vitreous hemorrhage).

Keywords: conbercept panretinal photocoagulation non-proliferative diabetic retinopathy diabetic macular edema
environmental and reproductive health risk for lewy body dementia

Conditions: Lewy Body Dementia; Parkinson Disease Dementia; Dementia With Lewy Bodies

Summary: the goal of this survey study is to identify environmental, occupational and reproductive health risk factors for lewy body dementia, which includes parkinson's disease dementia and dementia with lewy bodies. participants will complete a one-time survey online or over the phone that includes questions on environmental, occupational factors they may have been exposed to and on medical history including reproductive health. researchers will then compare the responses of people with lewy body dementia and people without parkinson's or memory/thinking problems to see which factors play a role in lewy body dementia. identifying risk factors can guide future treatment efforts and provide more insight to this dementia.

lewy body dementia, including parkinson's disease dementia and dementia with lewy bodies, is one of the most common dementias and does not have a cure for now. it can occur differently for women and men, although we are not sure why. the ratio of women to men for the disease prevalence changes with older age, suggesting a potential role for reproductive factors, particularly for women. environmental factors impact the risk for other types of dementia, although such factors have not been clearly described in lewy body dementia specifically. women and men may get exposed to different environmental and occupational risk factors, and the impact of factors can differ for women and men. by using one-time survey that can be completed online or over the phone, we will try to understand which environmental, occupational or reproductive health factors play a role in lewy body dementia for women and men. by comparing the survey responses of people with lewy body dementia and people without parkinson's or memory/thinking problems, we aim to identify specific risk factors for women and men that can guide future treatment efforts and provide more insight into this dementia.

Eligibility criteria:
inclusion criteria: * for participants with lewy body dementia: clinical diagnosis of lewy body dementia (parkinson's disease dementia or dementia with lewy bodies) * for controls: normal cognition * implication of consent to participate by stating consent verbally over the phone or by selecting the appropriate response on the online survey to indicate consent exclusion criteria: * for controls: parkinson's disease or dementia diagnosis
a high protein diet and weight maintenance

Conditions: Obesity

Summary: an investigation into long term weight maintenance using a high protein or high carbohydrate diet, after a large and rapid weight loss.


Eligibility criteria:
inclusion criteria: * healthy men and women with a bmi \>27kg/m2 with co-morbities or bmi \>30kg/m2 exclusion criteria: * people with type ii diabetes or other endocrine disorders, women who were pregnant or breastfeeding or planning to become pregnant

Keywords: obesity weight loss weight maintenance vled
feasibility of ethanolization of vein of marshall with specific catheter in atrial fibrillation ablation

Conditions: Atrial Fibrillation

Summary: in patients with persistent af (psaf), ablation limited to pulmonary vein (pv) isolation is the most straightforward approach, but results only in 50% of arrhythmia freedom at 1 year follow-up. substrate modification strategies have failed to demonstrate their superiority with variable reported success rate. the marshall network is a highly arrhythmogenic structure that has not been systematically targeted so far, probably because of the absence of dedicated tools to make its ablation simple and easy. we sought to investigate the use of a specific catheter for visualization and ethanolization of vein of marshall allowing to systematically include this target in the ablation set. the main objective of this study is to demonstrate the feasibility to use the targeted endovascular delivery (ted) catheter specifically for visualization and ethanolization of vein of marshall.


Eligibility criteria:
inclusion criteria: * suitable candidate for catheter ablation of atrial fibrillation defined as: * history of symptomatic persistent atrial fibrillation * redo procedure for persistent af or paroxysmal af with isolated pv and no history of ethanol infusion in the vom. * age \> 18 years of both genders * patient affiliated or beneficiary of social security scheme * free, informed and written consent signed by the participant and the principal investigator (at least at the inclusion date and before all exams required for the clinical research) * effective contraception for women of childbearing potential exclusion criteria: * minor * documented left atrial thrombus or another abnormality which precludes catheter introduction * contraindication to anticoagulation therapy (heparin, warfarin, or novel oral anticoagulant \[noac\] * contraindication to iodinated contrast product xenetix® (iobitridol hypersensivity or at one of these excipients, history of major immediate reaction or cutaneous reaction to xenetix® infusion, thyrotoxicosis) * hypersensitivity to ethanol * unstable angina or ongoing myocardial ischemia * myocardial infarction within 3 months prior to inclusion * congenital heart disease, where the underlying abnormality increases the ablation risk * severe bleeding, clotting or thrombotic disorder * pregnant, parturient or nursing women * unable or unwilling to provide written informed consent * patient detained by judicial or administrative order * patient under psychiatric care * patient admitted in a social or healthcare establishment for any purpose other than the research * subject to a legal protection order (guardianship, patient under legal protection)

Keywords: persistent atrial fibrillation pulmonary vein isolation catheter ablation ethanolization ligament of marshall vein of marshall
the effect of probiotics on the rate of recovery of inflammatory bowel disease exacerbation, endothelial function, and markers of inflammation

Conditions: Crohn's Disease; Ulcerative Colitis

Summary: fifty patients will get probiotics (109 bacteria \[l. acidophilus, b. bifidum, s. thermophilus, l. rhamnosus, l. casei\] in 2 capsules) and half will get placebo (2 capsules that look the same like the probiotic capsules and will contain microcrystalline cellulose, artificial brown color, magnesium strearate, and silica dioxide). the patients and the staff will be blinded to the identity of the study medications. each patient and volunteer will get the study medication for 6 weeks and will be evaluated twice - before enrollment and after 6 weeks of treatment. routine clinical management will continue - with regular treatment as needed. each individual will be studied for changes in biochemical inflammatory and immunological markers and changes in flow medicated diameter that will be measured by the brachial artery method (that is evaluating endothelial function). every patient will be evaluated for his/her ability to produce endothelial progenitor stem cells (epcs).


Eligibility criteria:
inclusion criteria: * patients with ulcerative colitis and crohns' disease exclusion criteria:. * notable caveats are that arteries smaller than 2.5 mm

Keywords: crohn's disease activity index cdai
trial of simvastatin for the treatment of severe asthma

Conditions: Severe Asthma

Summary: this purpose of this clinical trial is to determine if a statin drug, simvastatin, added to inhaled corticosteroids and bronchodilators can reduce systemic and airway inflammation, improve lung function and symptoms, and reduce acute exacerbations in patients with severe asthma who are already on controller inhaler therapy. this proposed investigator-initiated, single-center, early phase ii, cross-over, randomized clinical trial, titled "randomized trial of simvastatin for the treatment of severe asthma", will be conducted at the university of california, davis medical center (ucdmc) in sacramento, ca. this trial will evaluate simvastatin for treatment of asthma in subjects with severe asthma (as defined by the american thoracic society (ats)), who are already taking inhaler controller therapy. the investigators plan to enroll 24 patients with severe allergic asthma. the investigators hypothesize that treatment with simvastatin 40 mg (administered once daily) will not only improve indicators of airway and systemic allergic/th2 inflammation, but will also reduce acute exacerbations and improve lung function. all patients will be on standard controller therapy including appropriate doses of inhaled corticosteroids and long-acting bronchodilators.

see above.

Eligibility criteria:
inclusion criteria: 1. statin-naïve adults \>18 years old with the ats definition of severe asthma, 2. on ics and laba, 3. confirmation of allergic asthma (serum ige \>100 ku/l, positive radioallergosorbent test (rast) panel, and/or peripheral blood absolute eosinophil count of ≥700/mm3), 4. clinically stable for 4 weeks. exclusion criteria: 1. baseline fev1 \<30% predicted, 2. current smokers or ex-smokers with \>5 pack-years of smoking history, 3. pregnant women, nursing/lactating mothers, or women of childbearing potential who are actively attempting to become pregnant, 4. nasal or sinus surgery or trauma within 3 months of study participation, 5. ischemic heart disease, 6. liver disease, and 7. the concurrent use of the following medications (amiodarone, verapamil, diltiazem, gemfibrozil, cyclosporine, antifungal azoles (itraconazole, ketoconazole, or voriconazole), and danazol.

Keywords: severe asthma simvastatin allergic airway inflammation
study of fentanyl-propofol-emla of l.m.x4 technique for bone marrow aspiration

Conditions: Bone Marrow Disease; Pain

Summary: st. jude children's research hospital is studying the best ways to prevent pain during and after procedures such as bone marrow aspiration and lumbar puncture with intrathecal (in the spinal fluid) chemotherapy. researchers will study the effectiveness of combining anesthetics (medicines that help people sleep) and analgesics (medicines that relieve pain). researchers believe that a combination of fentanyl (analgesic) and propofol (anesthetic), along with applying the skin-numbing-cream emla or l.m.x4™ on the area where the procedure is performed, will provide better pain control. each patient enrolled on this study will have three different anesthetic combinations for three different procedures, in order to determine which combination worked best for each child.

the study focusses on the following primary aims: * to compare 0.5 mg/kg versus 1.0 mg/kg of fentanyl to control pain in patients who have a bmt/lpit procedure in the context of propofol anesthesia and topical anesthesia with emla or l•m•x 4™cream (or when necessary, lidocaine for injection). * to compare placebo versus fentanyl (0.5 mg/kg or 1.0 mg/kg) in these same patients. the first bmt/lpit for which patients receive any fentanyl will be used in this comparison. the study focusses on the following secondary aims: * to determine which dose regimen ensures best conditions to perform bone marrow aspiration (lack of motion) and maintains hemodynamic and respiratory stability as indicators of adequate levels of analgesia during bone marrow aspiration. * to evaluate the safety and complications for each dose regimen.

Eligibility criteria:
inclusion criteria: * patients undergoing bone marrow aspiration (unilateral), with lumbar puncture and intrathecal chemotherapy. * age 2 to 17 years * asa i-iii * patients with acute lymphoblastic leukemia or lymphoblastic lymphoma in remission or on the day of anticipated remission procedures occurring at the end of remission induction. * patients must have three anticipated bone marrow aspirates and lumbar punctures with intrathecal chemotherapy remaining in their treatment exclusion criteria: * newly diagnosed patients * patients with low platelet count (less than 50000) * patients undergoing bone marrow biopsy in addition to bone marrow aspiration * age less than 2 years or over 17 years * asa iv-v * patients taking opioid medication for pre-existent pain for more than 2 weeks at the time of the procedure * neurological impairment that would increase susceptibility to opioids (down's syndrome) * clinical contraindications for general anesthesia (large mediastinal mass) or specific use of propofol, fentanyl, emla, l•m•x 4™ or lidocaine for injection

Keywords: pain management bone marrow aspiration
incidence of methicillin resistant staphylococcus aureus (mrsa) carriage rates in resident physicians

Conditions: MRSA Colonization

Summary: one hundred new residents will be recruited prior to the start of residency and followed prospectively for a year. monthly nasal swabs will be performed to identify colonization with methicillin resistant staphylococcus aureus (mrsa).the proportion of study subjects colonized with mrsa at the end of 1 year will be calculated.

this is a prospective observational study looking at the incidence of mrsa colonization. new residents will be monitored every month with nasal swabs.we would like to elucidate factors responsible for mrsa colonization in healthcare workers.we would like to see if health care workers who are colonized spontaneously cleared mrsa and if there was any factors involved. nasal swabs will be plated on the spot by trained individuals and the plates then incubated for 48 hours. plates will be read by microbiologist after incubation.

Eligibility criteria:
inclusion criteria: * study subjects will be newly appointed residents at the ou medical center exclusion criteria: * previous mrsa infection * current use of mupirocin

Keywords: mrsa contact isolation incidence
evaluation of ceftaroline fosamil versus a comparator in adult subjects with community-acquired bacterial pneumonia (cabp) with risk for methicillin-resistant staphylococcus aureus

Conditions: Infections

Summary: the purpose of this study is to determine whether ceftaroline is effective and safe for the treatment of patients with community-acquired bacterial pneumonia (cabp) at risk for infection due to methicillin-resistant staphylococcus aureus (mrsa).

a multicenter, multinational, randomized, double-blind study to evaluate the efficacy and safety of ceftaroline fosamil versus ceftriaxone plus vancomycin in adult subjects with community-acquired bacterial pneumonia at risk for infection due to methicillin-resistant staphylococcus aureus.

Eligibility criteria:
inclusion criteria: * subjects are required to meet all of the following inclusion criteria: 1. male or female, ≥ 18 years old 2. presence of cabp requiring hospitalization 3. presence of cabp meeting the following criteria: i. confirmed pneumonia (new or progressive pulmonary) ii. acute illness (≤ 7 days' duration) with at least 3 clinical signs or symptoms consistent with a lower respiratory tract infection mrsa risk factors • mrsa-positive blood culture or respiratory specimen or a risk factor for mrsa such as a history of colonization with mrsa exclusion criteria: * subjects must not meet any of the following exclusion criteria at baseline: 1. history of any hypersensitivity or allergic reaction to any β-lactam antimicrobial 2. suspected or microbiologically-documented infection with a pathogen known to be resistant to any of the study drugs 3. non-infectious causes of pulmonary infiltrates (eg, pulmonary embolism, chemical pneumonitis from aspiration, hypersensitivity pneumonia, congestive heart failure) 4. more than 24 hours of potentially effective systemic antibacterial therapy for cabp within 96 hours before randomization 5. end-stage renal disease \[creatinine clearance (crcl) \< 15\], including hemodialysis 6. evidence of significant hepatic, hematological, or immunocompromising condition

Keywords: infections teflaro cephalosporin ceftaroline antibiotics pneumonia
acid-suppressing drugs pregnancy asthma offspring study

Conditions: Asthma in Offspring

Summary: the purpose of this study is 1. to estimate the association between prenatal exposure to proton pump inhibitors (ppis) and the risk of asthma during childhood. 2. to estimate the association between prenatal exposure to h2-receptor antagonists (h2ras) and the risk of asthma during childhood.

a cohort study on the association between acid-suppressing drugs in pregnancy and asthma in the offspring

Eligibility criteria:
inclusion criteria: - females aged 18-45 years with at least one pregnancy between 1 january 1995 - 31 december 2010 (see study population description) exclusion criteria: - males, females below age 18 and 45 years and above (see study population description)

Keywords: asthma, acid-suppressing drugs, pregnancy, epidemiology
detection of influenza or sars-cov-2 infection by ims of nasal air sampling

Conditions: Influenza

Summary: multicapillary ion mobility spectrometry of nasal air aspirates shall be investigated as screening tool for the detection of influenza and sars-cov-2- infection.

bacterial infections can be distinguished by analysis of the volatile organic compounds found in breath. in patients with suspected influenza infection, nasal air samples will be taken and analyzed by multicapillary ion mobility spectrometry (mcc ims). routinely all patients undergo polymerase chain reaction (pcr) analysis of nasopharyngeal swabs for influenza. mcc ims spectra will be compared between infected and non infected patients by cluster analysis and discrimination analysis. if the number of infected patients exceeds 50 an additional validation cohort will be investigated sequentially otherwise validation will be performed during the influenza epidemic 2021. due to decreasing numbers of influenza-a- infections study was opened to also include patients with suspected sars-cov-2 infections.

Eligibility criteria:
inclusion criteria: * suspected influenza infection exclusion criteria: * later than 48h after admission and detection of influenza infection * later than 32 days after admission and detection of sars-cov-2- infection * no written consent
thrombin generation and thrombus degradation in cerebral venous thrombosis : clinical and radiological correlations

Conditions: Cerebral Venous Thrombosis

Summary: cerebral venous thrombosis is considered as a rare type of stroke with an annual incidence of 3 to 4 per million people. it occurs generally in young patients (mean age of occurrence = 40 years) and principally in young females (75%) generally in pregnancy or oral contraceptive use situations. the onset may be acute (less than 2 days), subacute (between 2 and 30 days) or chronic (more than 30 days). the clinical presentation is highly variable and includes patients with only a mild headache, others with focal neurological deficits and a few with a dramatic syndrome and a coma. moreover the evolution can be very different with unpredictable outcome: more often it is favorable with a low mortality rate, but in some cases it can be a worse course. the aim of this study is to evaluate the correlation of some biological markers: thrombin generation test and d-dimers (marker of fibrin generation and degradation) with the type of onset or the wide spectrum of clinical presentations or the different modes of evolution. all patients over 16 years ago may be included in the program when cvt diagnosis is proved by magnetic resonance angiography (mra). for each included patient, there are four blood assays: the first just at the time of diagnosis and before the beginning of treatment, the second before the beginning of the oral anticoagulant treatment. the third assay is done in the third month at the time of a mra. the last assay is made one month after the end of the anticoagulant treatment or in 12th month after the beginning of the disease if the treatment goes on. for each sample, the investigators perform a thrombin generation test and a d-dimers measurement.


Eligibility criteria:
inclusion criteria: * patients over 16 years old hospitalized with an acute cerebral venous thrombosis, confirmed by by cerebral imaging

Keywords: cerebral venous thrombosis thrombin generation d-dimers clinical evolution